Search
Thalagen
go.drugbank.com/drugs/DB17714ExperimentalThalagen is a branded product developed by San Rocco Therapeutics.
Human Rho(D) immune globulin
go.drugbank.com/drugs/DB11597ApprovedIt was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults. … Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn).
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Hydroxocobalamin
go.drugbank.com/drugs/DB00200ApprovedInvestigationalHydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency.
Sarracenia Purpurea
go.drugbank.com/drugs/DB13965ApprovedWithdrawnIt was used as an injectable pain reliever and during the 19th century, _Sarracenia purpurea_ was used as a treatment of smallpox [A32509]. … It is widely distributed across North America and has been used as a traditional medicinal herb in many aboriginal communities [A32509, A32510].
Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigational[L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for … [A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational[A20301] When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding … Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older.
Tedizolid phosphate
go.drugbank.com/drugs/DB09042ApprovedThis product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Acyclovir
go.drugbank.com/drugs/DB00787ApprovedInvestigational[L7321] Acyclovir was granted FDA approval on 29 March 1982.[L7318] … [L7303,L7315,L7318,L7321,L7324,L7327] Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.
Phenylalanine
go.drugbank.com/drugs/DB00120ApprovedInvestigationalNutraceuticalPhenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.
Mixtures: TRAVASOL® SOLUCION BAL 8.5% SIN ELECTROLITOS, EAS ORAL 100 TABLET